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Objective. To determine the link between extraarticular manifestations (EAMs) and baseline characteristics in patients with axial spondyloarthritis (SpA), and to define their potentially differential prognostic value in 2 large, independent Belgian axial SpA cohorts with distinct recruitment periods.
Methods. Information on demographic and clinical characteristics and extraarticular manifestations (EAMs) was obtained from patients with axial SpA originating from the (Be)Giant (Belgian Inflammatory Arthritis and Spondylitis) cohort, which includes consecutive axial SpA patients whose data have been collected since 2010, and from the ASPECT (Ankylosing Spondylitis Patients Epidemiological Cross-sectional Trial) cohort, a Belgian registry of cross-sectional data collected between February 2004 and February 2005 from consecutive patients with ankylosing spondylitis (AS) or probable AS.
Results. Among the 1,250 Belgian patients studied, disease duration was associated with risk of developing inflammatory bowel disease (IBD), with an increase in risk by 20% per 10 years of disease duration (relative risk [RR] 1.2, P = 0.026), and associated with risk of developing acute anterior uveitis, with an increase in risk by 30% per 10 years of disease duration (RR 1.3, P < 0.001). In the subgroup of 171 newly diagnosed patients with prospective follow-up data, higher mean C-reactive protein levels over time were demonstrated in those with acute anterior uveitis or IBD compared to those without EAMs or those with psoriasis alone (each P = 0.01).
Conclusion. The risk of developing acute anterior uveitis or IBD, but not psoriasis, in patients with axial SpA seems to increase with disease duration and appears to be linked to a higher cumulative exposure to inflammation, thus providing a possible explanation for the differential structural progression observed in those with axial SpA.
The prevalence of extraarticular manifestations (EAMs) in patients with ankylosing spondylitis (AS) is well-known, with hazard ratios (HRs) compared to the general population of 15.5 for acute anterior uveitis, 1.5
The ASPECT cohort was collected and supported by Merck Sharp & Dohme. The (Be)Giant cohort was supported by an unrestricted grant from AbbVie. Dr. Elewaut's work was supported by Scientific Research-Flanders, the Research Council of Ghent University, and the Belspo Agency (Interuniversity Attraction Pole grant Devrepair; project P7/07). 1 for skin psoriasis, and 3.3 for inflammatory bowel disease (IBD) (1) . Similarly, increasing frequencies of EAMs in different stages of disease have been reported across observational cohorts such as the GESPIC (German Spondyloarthritis Inception Cohort) and the DESIR (Devenir des Spondyloarthropathies Indiff erenci ees R ecentes) cohort of patients with inflammatory back pain (IBP) (2, 3) . Nevertheless, research on the potential value of these EAMs as tools for the stratification of patients and for disease prognosis is scarce.
In patients with axial SpA, radiographic progression has been shown to be associated with baseline clinical characteristics, such as an elevated C-reactive protein (CRP) level, hip involvement, HLA-B27 positivity, smoking, structural damage, and evidence of inflammation on magnetic resonance imaging (MRI) (4-6). Meanwhile, acute anterior uveitis in patients with axial SpA has been found to be strongly associated with the presence of HLA-B27 (7, 8) , while gut inflammation has been shown to be associated with the severity of sacroiliitis (9) , both of which were previously recognized as a predisposing factor for structural progression in axial SpA. However, the presence of psoriasis in patients with axial SpA has been associated with less evidence of inflammation on MRI and less frequent radiographic damage (10) .
Therefore, in the present study our goal was to examine any potential link of psoriasis with baseline clinical characteristics in patients with axial SpA in comparison to that in axial SpA patients who develop acute anterior uveitis or IBD, and to explore the role of exposure to systemic inflammation over time-with CRP as a surrogate marker-as a potential explanation for the discrepancy in structural progression between patients displaying these different types of EAMs. We anticipated that the axial SpA patients with IBD and/or acute anterior uveitis would display more inflammation, rendering them more prone to structural progression.
PATIENTS AND METHODS
Patients and study design. The analyzed data originated from the (Be)Giant (Belgian Inflammatory Arthritis and Spondylitis) cohort, which includes consecutive patients diagnosed as having SpA since 2010, and from the ASPECT (Ankylosing Spondylitis Patients Epidemiological Cross-sectional Trial) cohort, which is a large cohort of consecutive patients diagnosed as having AS or probable AS, from whom data were obtained between February 2004 and February 2005.
The (Be)Giant is an observational cohort comprising both patients with peripheral SpA and patients with axial SpA, of which the subset of 227 patients with axial SpA was analyzed in the present study, and part of this cohort has been previously described in a study by Van Praet et al (11) . The ASPECT registry is a Belgian cross-sectional database containing information on 847 axial SpA patients who fulfilled the modified New York criteria for AS (12) . The aim of ASPECT was to describe the phenotype of an average axial SpA patient in a Belgian rheumatology practice (6, 12) prior to the initiation of anti-tumor necrosis factor (anti-TNF) therapy for axial SpA. Another 176 patients in the ASPECT cohort who did not fulfill the criterion of radiographic damage in the modified New York criteria were classified as having probable AS. Similar to the (Be)Giant cohort, all patients in the ASPECT cohort received their clinical diagnosis of axial SpA from a rheumatologist prior to inclusion.
Considering that some of the patients in the ASPECT cohort had received a diagnosis of probable AS, the baseline characteristics did not differ from those in a contemporary population of patients with nonradiographic axial SpA. Moreover, 76.6% of patients (108 of 141 [n = 35 with missing data]) were HLA-B27 positive, of whom 63.9% (69 of 108) fulfilled the Assessment of SpondyloArthritis international Society (ASAS) clinical criteria for SpA (13) , based on the combined presence of HLA-B27 positivity and ≥2 typical characteristics of SpA (i.e., IBP, arthritis, enthesitis, acute anterior uveitis, skin psoriasis, IBD, family history, and elevated CRP level). Unfortunately, no data on dactylitis and/or the patients' response to nonsteroidal antiinflammatory drug (NSAID) therapy were available, nor were there any MRI data available at that time. Therefore, this cohort of patients with probable AS mirrors the phenotype of patients who we currently classify as having nonradiographic axial SpA (6) . By introducing a large cohort of axial SpA patients who received their diagnosis in an unbiased manner (due to the introduction of EAMs as a criterion in the 2009 ASAS criteria for SpA), an extra dimension was added to the analysis.
Both observational cohorts and the study protocol were authorized by the local ethics committee of the University Hospital of Ghent. Written informed consent was obtained from all patients prior to inclusion.
Variables. Sex, age, disease duration, HLA-B27 status, enthesitis, arthritis, CRP level, fulfillment of disease classification criteria, family history, and scores on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (scale 0-10) (14) and Bath Ankylosing Spondylitis Functional Index (BASFI) (scale 0-10) (15) were collected from patients in the ASPECT and (Be)Giant cohorts. The outcome measures (EAMs, psoriasis, IBD, acute anterior uveitis, arthritis, and enthesitis) were recoded into dichotomous variables as present versus absent. Paradoxical psoriasis was not included in the analysis. In the (Be)Giant cohort, only EAMs documented by a physician in the electronic patient file were included. In the ASPECT cohort, past or present EAMs were collected by the treating rheumatologist at the time of inclusion in the cohort. For the prospective analysis, data on the CRP level were collected through a thorough file search within the electronic files of the patients who had not yet been treated with anti-TNF agents, both prospectively and retrospectively up to 1 year prior to diagnosis and up to 4.5 years after inclusion. Patients were included when at least 2 CRP values were available, obtained over at least a 6-month interval. CRP values collected by the general practitioner were not included, as these were more likely to represent an infectious episode.
Statistical analysis. The statistical analysis was performed using SPSS version 24. Significance was set at an alpha level of 0.05.
The nonparametric Mann-Whitney U test was applied to asses any differences in the continuous variables between the (Be)Giant and ASPECT cohorts, and between the patients with acute anterior uveitis and/or IBD and the patients without EAMs or those with skin psoriasis only. For variables with a parametric distribution, the Student's t-test was applied. The chisquare test for a 2 9 2 table was employed to identify differences in sex, HLA-B27 status, presence of acute anterior uveitis, presence of psoriasis, and presence of IBD between the cohorts and subgroups, as well as to identify differences in family history, presence of arthritis, and presence of enthesitis.
The association of the presence of EAMs with different patient characteristics was analyzed by multiple logistic regression. Variables were selected on the basis of clinical relevance. The number of variables entered in the model was based on~10 events per variable. The Hosmer and Lemeshow goodness-of-fit test was evaluated for model fit, with no signs of overfitting observed. The relative risk (RR) associated with the odds ratio (OR) was calculated using the following formula, as recommended by Grant (16) 
, where p represents the baseline risk. Since the CRP level was collected from patients at the time of diagnosis in the (Be)Giant cohort, but was collected at a cross-sectional inclusion time point in the ASPECTcohort, an interaction between CRP and the cohort variable was included in the model to correct for differential effect across the cohorts. However, this interaction was not significant. There were no signs of collinearity between the variables. Interactions of the variables with the cohort variable were explored, but none were significant. Sensitivity analyses in which we excluded patients treated with anti-TNF therapy were conducted.
In the prospective analysis, the cumulative exposure to log-transformed CRP (log[CRP]) over time was calculated by linear mixed models analysis, with the group and time point (and their interaction) as fixed factors and subjects as a random factor. Since the outcome variable CRP was log-transformed, the results of this model are presented on the original scale (mg/dl) as the geometric mean, with corresponding 95% confidence interval. Similarly, the proportion of patients with measurements of CRP above the cutoff level of 0.5 mg/dl per group was analyzed by mixed logistic regression, with the group and time point as fixed factors and subjects as a random factor.
RESULTS
Baseline characteristics of the patients. The baseline characteristics of the 928 patients who fulfilled the modified New York criteria for AS, including 847 in the ASPECT cohort and 81 in the (Be)Giant cohort, and 322 patients with nonradiographic axial SpA, including 176 in the ASPECT cohort and 146 in the (Be)Giant cohort, were compared across the cohorts. All of the baseline demographic and clinical characteristics of these patients (Table 1) were consistent with the data reported previously in cohorts of patients with early or established disease. The higher proportion of patients in the (Be)Giant cohort with elevated CRP levels can be explained by the fact that the serum collection took place at the time of diagnosis as opposed to the time of inclusion, regardless of time of diagnosis, in the ASPECT cohort.
Cross-sectional analysis of EAMs in patients with axial SpA. Prevalence of EAMs at inclusion. The prevalence of EAMs at the time of inclusion was not significantly different across the cohorts despite the inclusion of patients at different stages of disease. Overall, 34.4% of patients in the (Be)Giant cohort had already experienced EAMs prior to inclusion, as compared to 39.7% of patients in the ASPECT cohort experiencing EAMs by the time of inclusion (P not significant). Overlap between the different EAMs (psoriasis, IBD, and acute anterior uveitis) appeared to be limited, even in patients with Features associated with EAMs. The presence or history of any EAM at the time of inclusion was significantly associated with disease duration in analyses corrected for age, sex, classification criteria present, BASFI score, BASDAI score, CRP level, and HLA-B27 status. The overall increase in the risk of developing EAMs was 20% per 10 years of disease duration (RR 1.2, P < 0.001). Interestingly, we also found a significant association between the risk of EAMs and the time point of inclusion (pre-ASAS criteria versus post-ASAS criteria), with a 30% increase in risk in patients considered to have met the ASAS criteria (RR 1.3, P = 0.047). This finding might be explained by the implementation of the ASAS criteria, which incorporates the presence of EAMs. Conceivably, this made physicians more aware of these features of SpA, which would lead to referral. Disease duration nevertheless remained an independent predictor of the risk of developing EAMs in multivariate analyses, after correction for multiple variables, including the specific cohort as a factor.
We noticed that patients in the ASPECT cohort who were already taking anti-TNF medication at baseline were more likely to have already encountered an EAM (RR 1.5, P = 0.004). This was clearly manifested in patients who developed IBD, in whom a significant association with taking an anti-TNF agent at the time of inclusion was noted, with an increase in the RR of 140%. Indeed, uncontrolled IBD is more likely to be recognized as an indication for biologic therapy than is psoriasis or acute anterior uveitis.
Moreover, a 20% increased risk of developing IBD was noted per 10 years of disease duration in the patient cohorts, in addition to an increase in the risk by 70% in those with HLA-B27 negativity. Similarly, acute anterior uveitis was linked to disease duration, with an increase in risk by 30%, and, as expected, those with HLA-B27 positivity also had an increased risk, by 90%. In contrast, the risk of developing skin psoriasis as an EAM was solely associated with HLA-B27 negativity, with an increase in risk of 90%, and with male sex, with an increase in risk of 50% (Table 2 ).
Another surrogate of the inflammatory burden, peripheral arthritis, showed a marked increase in risk, by 20%, per 10 years of disease duration (RR 1.2, P < 0.001), whereas in those receiving anti-TNF therapy at baseline, the increase in risk was 50% (RR 1.5, P = 0.005). However, with regard to enthesitis, the association with disease duration did not reach statistical significance (P = 0.096) (data not shown).
Linkage of IBD and acute anterior uveitis to cumulative exposure to inflammation in patients with axial SpA in a prospective analysis. A striking observation was that only IBD and acute anterior uveitis appeared to be associated with disease duration in the patient cohorts, which may be reflective of a higher cumulative load of inflammation over time in these patients. To test this hypothesis, a subanalysis of 171 patients from the (Be)Giant cohort with newly diagnosed axial SpA for whom prospective followup data were available was conducted. A comparison of the geometric mean CRP value over time was made between patients who developed IBD or acute anterior uveitis and those who did not.
Overall, 5.3% of patients (9 of Because microscopic gut inflammation occurs iñ 50% of patients with SpA and is linked to more severe sacroiliac inflammation, we also determined the presence of gut inflammation in relation to the presence of clinically overt EAMs. Gut inflammation (including both acute and chronic microscopic gut inflammation and clinically overt IBD) was present in 60% of patients in the IBD and/or acute anterior uveitis group compared to 41.8% of patients in the group without EAMs or with psoriasis only (P = 0.06). Chronic gut inflammation (which resembles Crohn's disease) and/or overt IBD was present in 47.5% of patients in the IBD and/or acute anterior uveitis group compared to only 21.5% of patients in the subset without EAMs or with psoriasis alone (P = 0.004) ( Table 3) .
Both groups presented with high disease activity at baseline, as defined by an Ankylosing Spondylitis Disease Activity Score of >2.1 (Table 3 ). The mean follow-up time in patients with acute anterior uveitis or IBD and patients without EAMs or with psoriasis alone was 28.9 months and 26.9 months, respectively (P not significant).
Consistent with our hypothesis, we observed significantly higher geometric mean CRP values over time in patients with IBD or acute anterior uveitis compared to those without EAMs or those with psoriasis alone (P = 0.01) (Figure 3 ). In addition, in more than 37% of the patients with IBD and/or acute anterior uveitis, the CRP measurements reached ≥0.5 mg/dl, compared to 24.5% of patients without EAMs or those with psoriasis alone displaying a CRP level of ≥0.5 mg/dl (P = 0.057).
Thus, patients with axial SpA who develop IBD or acute anterior uveitis experience higher levels of CRP over time, as well as a higher frequency of gut inflammation and AS, as compared to axial SpA patients without EAMs or with skin psoriasis only.
DISCUSSION
In this study, a striking association between acute anterior uveitis, IBD, and disease duration in axial SpA was found. Surprisingly, this was not the case for psoriasis. We show that this duality could reflect an overall differential cumulative exposure to inflammation over time, with higher exposure in patients with IBD and/or acute anterior uveitis. To our knowledge, this is the first study to link a discriminative association of IBD and/or acute anterior uveitis, as opposed to psoriasis, to structural progression in axial SpA. It is well-known that the genetic predisposition and cytokine-driven pathways of AS and psoriasis, acute anterior uveitis, and IBD are closely linked (1, (17) (18) (19) (20) (21) . The common physiopathology in the spectrum of SpA is illustrated by the shared success of anti-TNF therapy. Nevertheless, the variable success of other modes of action, such as the interleukin-17 (IL-17) and anti-IL-12/ IL-23 pathways (22) , illustrates the differences in tissuespecific responses.
The major histocompatibility complex region HLA-Cw6 has been shown to be increased in frequency in patients with psoriatic skin disease, whereas HLA-B27 was more closely related to joint disease in patients with psoriatic arthritis (23) . Besides the lack of association with HLA-B27 in the present and previous studies (24, 25) , only a few shared loci were found between patients with AS and patients with psoriasis. In sharp contrast, much more overlap was reported between patients with AS and patients with IBD, with at least 23 shared loci (26) . Likewise, the genetic overlap between AS and acute anterior uveitis is much greater than with psoriasis (27) .
In addition to the genetic component, imaging features in patients with axial SpA with or without psoriasis (or psoriasis patients with spondylitis) seem to present differently, with sacroiliitis being preferentially located unilaterally, aberrant expression of syndesmophytes, and more frequent involvement of the cervical spine (28) (29) (30) (31) (32) . Consistent with the results of the present study, psoriasis was associated with less inflammation, as evidenced on MRI of the spine and sacroiliac joints, and with less radiographic damage in a follow-up study of patients with early disease (10) . Recently, Costantino et al reported on the possible existence of different phenotypes in the DESIR cohort of patients with IBP, with the analysis showing clustering of patients based on specific phenotypes, such as a cluster of patients with predominantly axial symptoms and a better response to NSAIDs in contrast to a cluster of patients with IBP and more prominent peripheral disease, consisting of arthritis, dactylitis, and enthesitis closely linked to psoriasis (33) . Accordingly, our study findings revealed a similar trend toward a higher range of swollen joint counts in patients without EAMs or in patients displaying psoriasis.
A similar overall prevalence of the different EAMs was observed at the time of inclusion in both cohorts, which mirrors data from the DESIR cohort and the GESPIC cohort of patients with AS or nonradiographic axial SpA (2, 3) . In concordance with our results, the prevalence of acute anterior uveitis in AS has been reported to increase with disease duration or with duration of IBP (34) (35) (36) . However, up until now, no investigators have been able to determine the association of IBD or psoriasis with disease duration, which is most likely attributable to the underrepresentation of patients with a shorter disease duration (34) . Similarly, in the GESPIC cohort, no significant difference in EAM frequencies was observed between axial SpA patients with >5 years of symptom duration and axial SpA patients with ≤5 years of symptom duration, although the prevalence of both IBD and acute anterior uveitis was distinctly lower compared to that in other cohorts containing patients with a longer disease duration. Notably, this was not the case for psoriasis (3) .
Remarkably, even in those with longstanding disease, overlap between EAMs appeared to be rather limited in axial SpA. Nevertheless, in a study by Wendling et al, an association between IBD with SpA and psoriasis in a wellestablished cohort of patients with IBP was found (36) , while a lower prevalence of acute anterior uveitis in patients with IBD and SpA as compared to patients with classic AS has been reported (35, (37) (38) (39) . These seemingly contradictory results might be explained by overlap with peripheral disease, in which the link with EAMs is clearly different.
In the present study, a higher mean CRP level over time was observed in axial SpA patients with IBD or acute anterior uveitis compared to patients without EAMs or psoriasis only. Since CRP is a key predictor of radiographic progression over time, it may contribute to the divergent radiographic findings between these groups. Although our findings are indicative of an association between the presence of certain EAMs and CRP levels, these findings do not necessarily portray a causal relationship. The appearance of IBD or acute anterior uveitis may just as well be an expression of cumulative exposure to systemic inflammation. Alternatively, patients with IBD or acute anterior uveitis might simply develop more inflammation. Interestingly, patients with IBD and/or acute anterior uveitis not only displayed a higher CRP level over time, but also had a significantly higher frequency of AS at inclusion. In addition, a higher proportion of patients with IBD and/or acute anterior uveitis had gut inflammation, especially chronic gut inflammation, which in turn has been linked to more severe inflammation of the sacroiliac joints on MRI (9) . The results of this analysis support the hypothesis that the overall exposure to systemic inflammation differs according to the spectrum of EAM in patients with axial SpA, potentially entailing a higher risk of structural progression in patients with IBD and/or acute anterior uveitis as compared to patients with psoriasis. As these EAMs frequently seem to occur early in the disease, and prior to diagnosis, they may be an early indication of risk of progressive disease.
Possible limitations of this study include the crosssectional design of the ASPECT study compared to the prospective nature of the (Be)Giant cohort. However, by including the cohort as a variable in our model, we corrected for this potential confounder, rendering our results independently associated with the presence of EAMs. Likewise, by including an interaction of CRP with the cohort in our model, we corrected for a possible differential effect of CRP in the different cohorts, as CRP values at diagnosis were not available in the ASPECT cohort, thus explaining the lower CRP values in the ASPECT patients compared to the (Be)Giant patients at baseline.
From a conceptual point of view, our data suggest that we should reconsider whether acute anterior uveitis, IBD, and psoriasis are 3 entities equally associated with axial SpA, even though a strong association between psoriasis and peripheral SpA has been established in the past. Overall, the risk of developing acute anterior uveitis or IBD, but not psoriasis, seems to increase with disease duration in axial SpA and appears to be linked to a higher cumulative exposure to inflammation.
